Evaluating the Efficiency of Calcipotriol Plus Betamethasone Dipropionate Cutaneous Pad Cream for the Topical Treatment of Mild to Moderate Plaque Psoriasis in Italy

Speaker(s)

Prignano F1, Campanati A2, Banerjee R3, Carles A3, Galván J3, Lorenzo-Herrero S4, Crespo C5, Cuervo J6
1Section of Dermatology, Department of Health Sciences, University of Florence, Florence, Tuscany, Italy, 2Dermatology Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Marche, Italy, 3Almirall S.A., Barcelona, Catalonia, Spain, 4Axentiva Solutions SL, Oviedo, O, Spain, 5Axentiva Solutions SL, Barcelona, B, Spain, 6Axentiva Solutions SL, Oviedo, Asturias, Spain

OBJECTIVES: The objective was to evaluate the efficiency of CAL/BDP PAD cream compared to gel formulations treating patients with mild to moderate plaque psoriasis in Italy.

METHODS: An incremental cost per responder analysis was conducted based on a recent pooled analysis of two phase 3, multicentre, randomized, investigator-blind, active, vehicle-controlled trials comparing the safety and efficacy of CAL/BDP PAD cream and CAL/BDP gel (NCT03308799 and NCT03802344). Clinical benefits were evaluated utilizing mPASI75 (modified-Psoriasis Area Severity Index with >75% improvement in the scale from baseline) and PGA (Physician Global Assessment) success. Also, quality-adjusted life years (QALY) for responders/non-responders were estimated. The time horizon was defined as eight weeks, according to the trials. Ex-factory drug costs (in € as of January 2024) were used. Clinical management was assumed to be the same for both alternatives. The weighted average cost of gel formulations was estimated following the market share of licensed products in Italy. Sensitivity analyses were conducted to test the impact of efficacy rates, drug consumption adjusted to real-life practice, and market share on the cost-per-responder analysis

RESULTS: CAL/BDP PAD cream showed a higher rate of responders versus CAL/BDP gel formulations: incremental response +9.8% for mPASI75 and +11.3% for PGA. Costs per success were significantly higher in CAL/BDP gel formulations: €314.63 vs €262.98 for mPASI75 and €340.27 vs €269.68 for PGA, despite the incremental cost per patient in CAL/BDP PAD cream (€7.95). Finally, CAL/BDP PAD cream showed as a highly efficient alternative over CAL/BDP gel in Italy: €81.15 for mPASI75, €70.38 for PGA and €1,062.96/QALY.

CONCLUSIONS: Based on the efficacy results from phase 3 controlled trials, CAL/BDP PAD cream represents an efficient treatment for managing patients suffering from mild to moderate plaque psoriasis in Italy. Further research, considering long-term outcomes, should be evaluated to complete the economic analysis.

Code

EE145

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)